Biomarkers may yield information relevant to disease outcome on three progressive levels: (i) as measurable endpoints of damage to proteins/amino acids, oxidised lipids, oxidised DNA bases, (ii) as functional markers of, for example, blood flow, platelet aggregation, or cognitive function, and (iii) as endpoints related to specific disease
I highly recommend this place." -Monica Arzani (Verified Customer) Semaglutide, a medication initially approved for the treatment of type 2 diabetes, has recently been approved for weight loss in adults who are overweight or have obesity
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the global collaborative network
The key difference lies in their mechanisms: Retatrutide activates three metabolic receptors (GIP, GLP-1, and glucagon) while Tirzepatide activates two (GIP and GLP-1)